Answer Summary

Members with KRAS G12 mutations shared their diverse treatment experiences, with many receiving Keytruda as part of their regimen, either... Read more

Members with KRAS G12 mutations shared their diverse treatment experiences, with many receiving Keytruda as part of their regimen, either alone or combined with chemotherapy drugs like carboplatin, pemetrexed, docetaxel, or cyramza, and one member taking the targeted therapy Lumakras (sotorasib) specifically for G12C. Several members described their treatment journeys, including one who achieved no evidence of disease after a year of immunotherapy, another who experienced stable disease before switching to a second-line treatment that finally showed shrinkage, and others navigating recurrence after initial surgery with optimism about their PD-L1 levels making them good candidates for Keytruda. A recurring theme was the importance of knowing the specific G12 variant (such as G12C or G12D) to access targeted therapies, managing side effects like rash and fatigue, staying positive through setbacks described as bumps in the road, and leaning on community support while adjusting to life with metastatic disease.